Ganaplacide/lumefantrine formulation moves into phase III trials for malaria
As the threat of resistance to current malaria treatments grows Novartis and MMV announce the decision to progress ganaplacide/lumefantrine- solid dispersion formulation (SDF) into Phase III development for the treatment of patients with acute uncomplicated malaria due to Plasmodium falciparum
As previously announced, a Phase II open-label, randomized controlled study was conducted in 524 adults and children with acute uncomplicated malaria due to Plasmodium falciparum infection. The ganaplacide/lumefantrine-SDF combination met the primary objective in both adults and children. In patients who received a once-daily dose of ganaplacide/lumefantrine-SDF during 3 days, response to treatment was similar to the rate observed in patients who received twice-daily artemether-lumefantrine control therapy during 3 days.
Planned to start in 2023, one large Phase III pivotal trial will compare the efficacy of ganaplacide/lumefantrine-SDF to the current ‘gold standard’ artemether-lumefantrine. The trial will be conducted in collaboration with the WANECAM 2 consortium, and will include partner clinical sites in Burkina Faso, Mali, Gabon and Niger as well as other sites in sub-Saharan Africa. Both Phase II and III studies receive funding from the European and Developing Countries Clinical Trials Partnership (EDCTP), which is supported by the European Union.
Related news and insights
PTC Therapeutics, Inc. announced that Upstaza (eladocagene exuparvovec) was granted authorization by the Medicines and Healthcare Products Regulatory Agency (MHRA) in Great Britain.
Spectrum Pharmaceuticals announced that the Company has received a Complete Response Letter (CRL) from the FDA regarding Spectrum’s New Drug Application (NDA) for poziotinib for the treatment of patients with previously treated locally advanced or metastatic non-small cell lung cancer harboring HER2 exon 20 insertion mutations.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced results from ESCAPE-TRD, a long-term, comparative, randomised, open-label phase IIIb clinical trial designed to evaluate the short- and long-term efficacy, safety and tolerability of flexibly dosed Spravato (esketamine nasal spray compared with quetiapine extended-release (XR), both in combination with a continuing selective serotonin reuptake inhibitor (SSRI) or serotonin and norepinephrine reuptake inhibitor (SNRI), in adults with treatment-resistant major depressive disorder (TRD).